Retrospective Study on the Incidence and Management of Anemia in Oncology

Cancer Clinical Trial

— RESPIRE  

Official title:

Retrospective Study on the Incidence and Management of Anemia in Oncology

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04779840
• Other study ID #: WP-2019-06
• Status: Completed
• Start date: May 20, 2020
• Est. completion date: January 20, 2021

Study information

• Verified date: February 2021
• Source: Weprom
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The incidence of anemia ranges from 20 to 75% depending on the type of cancer. It is often present at diagnosis and increases with specific treatments. It has an impact on overall survival and quality of life. Its origins are multiple (pure iron deficiency or functional, malnutrition, dyserythropoiesis, insufficiency renal, hemolysis, chemotherapy, radiotherapy, targeted therapies). Transfusion is the most common treatment offered in the management of anemia. The incidence of anemia and its consequences are often underestimated during cancer management. Recommendations were published in 2012. An inventory of the incidence of anemia before and after the publication of these recommendations are proposed in order to assess their impact on daily practice.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 349
• Est. completion date: January 20, 2021
• Est. primary completion date: January 20, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age = 18 years old,
• Follow-up for cancer justifying hospitalization,
• Presenting anemia defined by a hemoglobin level <11 g / dL,
• Patient not having objected to the collection of his data after oral and written information.

Exclusion Criteria:

• patients with a hemoglobin level = 11 g / dL,
• adult patients under guardianship, curatorship or deprived of liberty,
• pregnancy or breast-feeding in progress at the time of hospitalization.

Related Conditions & MeSH terms

• Anemia
• Cancer

Intervention

Other:
• anemia assessment
evaluation of anemia status

Locations

Country	Name	City	State
France	Centre Jean Bernard - Clinique Victor Hugo	Le Mans

Sponsors (1)

Lead Sponsor	Collaborator
Weprom

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Incidence of anemia	number of patient with anemia (<11.0 g/dL) upon admission to hospital on the number of patients hospitalized over the period	2 years
Secondary	Assessment of transfusion prescriptions	number of transfusions performed on the number of patients hospitalized over the period	2 years
Secondary	Assessment of erythropoiesis stimulating agents (EPO) prescriptions	number of prescriptions for erythropoiesis stimulating agents (EPO)	2 years
Secondary	Assessment of iron prescriptions	number of prescriptions of iron (oral and intravenous)	2 years
Secondary	Time between last transfusion and date of death	Delay between the date of the last transfusion and the date of patient's death	2 years
Secondary	overall survival	Delay between the enrollment date and the date of patient's death	2 years